According to Palatin Technologies's latest financial reports the company's current revenue (TTM) is $7.09 M. In 2022 the company made a revenue of $2.88 M an increase over the years 2021 revenue that were of $0.74 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $7.09 M | 146.2% |
2022 | $2.88 M | 286.68% |
2021 | $0.74 M | -264.75% |
2020 | -$0.46 M | -100.75% |
2019 | $60.38 M | 103.89% |
2018 | $29.61 M | -64.01% |
2017 | $82.27 M | |
2016 | N/A | |
2015 | N/A | -100% |
2014 | $12.95 M | |
2013 | N/A | -100% |
2012 | $0.04 M | -82.26% |
2011 | $0.25 M | -94.31% |
2010 | $4.49 M | -77.9% |
2009 | $20.33 M | 445.4% |
2008 | $3.72 M | -75.87% |
2007 | $15.44 M | -17.37% |
2006 | $18.69 M | 1.7% |
2005 | $18.38 M | 93.58% |
2004 | $9.49 M | 274.31% |
2003 | $2.53 M | 140.47% |
2002 | $1.05 M | 168.31% |
2001 | $0.39 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $89.65 B | 1,263,112.38% | ๐บ๐ธ USA |
AstraZeneca AZN | $47.61 B | 670,694.95% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $1.98 B | 27,824.55% | ๐บ๐ธ USA |
MediciNova MNOV | $1 M | -85.91% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $0.13 B | 1,750.09% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | $0.19 B | 2,617.08% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $0.48 B | 6,758.79% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | $0.01 M | -99.86% | ๐บ๐ธ USA |
Ardelyx ARDX | $0.12 B | 1,653.47% | ๐บ๐ธ USA |